Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
Multidimensional traction force microscopy reveals out-of-plane rotational moments about focal adhesions
2012 StandoutNobel
Triggering a Cell Shape Change by Exploiting Preexisting Actomyosin Contractions
2012 StandoutScienceNobel
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2009
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
2008
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
1993
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005
Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer
2006
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
2008 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials
2001
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Breast cancer
2016 Standout
Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy
1996
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
2006
Growth factors and oncogenes in breast cancer
1990
Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
1998
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
1991
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting
2000
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Drug development from marine natural products
2008 Standout
Cardiac tumours: diagnosis and management
2005
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
1994
Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy
1993
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
2001
Immunogenic cell death in cancer and infectious disease
2016 Standout
The influence of the boost in breast-conserving therapy on cosmetic outcome in the eortc “boost versus no boost” trial
1999
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
2005 StandoutNature
The efficacy of a combination of ondansetron, methyiprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy
1997
Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients
1995
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial
1996
Histological and molecular types of breast cancer: is there a unifying taxonomy?
2009
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
2002
Structural and functional features of central nervous system lymphatic vessels
2015 StandoutNature
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
2002 Standout
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
1996
Corrupt policemen: inflammatory cells promote tumor angiogenesis
2008
The molecular biology of breast cancer
1991
Surgical Management of the Breast
2013
Drug Treatment of Chemotherapy-Induced Delayed Emesis
1996
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Ten-Year Results of a Comparison of Conservation with Mastectomy in the Treatment of Stage I and II Breast Cancer
1995
Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801
1998 Standout
Genetic alterations in breast cancer
1995
Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer
1990
Collective cell migration in morphogenesis, regeneration and cancer
2009 Standout
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
2002 Standout
Current views on the function of the lymphatic vasculature in health and disease
2010
Targeting autophagy in cancer
2017 Standout
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
2002
Clonal evolution in cancer
2012 StandoutNature
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Treatment of Breast Cancer
1998
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Chemotherapy in Early Breast Cancer: When, How and Which One?
2014
TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function
2008 StandoutNature
An empirical assessment of validation practices for molecular classifiers
2011
Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family
2005
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2000
Age as prognostic factor in premenopausal breast carcinoma
1993
p73: Friend or foe in tumorigenesis
2002
A novel cyclin encoded by a bcl1-linked candidate oncogene
1991 StandoutNature
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
2002
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
1999
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
EID3 is a novel EID family member and an inhibitor of CBP-dependent co-activation
2005
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
2009 StandoutNobel
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Immuno-Navigator, a batch-corrected coexpression database, reveals cell type-specific gene networks in the immune system
2016 StandoutNobel
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
2011
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
2007
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
2000
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Spermidine in health and disease
2018 StandoutScience
Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
2011
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
2017 Standout
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
1990 StandoutScience
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity
2001
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
2006
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Second Malignancies After Treatment of Early-Stage Breast Cancer: Lumpectomy and Radiation Therapy Versus Mastectomy
2000
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
2013
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay.
1999
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
2004
Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer
1995
Evidence for Cardiomyocyte Renewal in Humans
2009 StandoutScience
Works of M. Spielmann being referenced
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
1988
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
2008
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
2007
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
2006
Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significance
1989
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis
2009
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer
1989
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
1990
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
1995
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience
1998
Risk factors for brain relapse in patients with metastatic breast cancer
2004
Surgical resection of pulmonary metastases. Up to what number?
1994
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
1996
Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin
1994
Dermal Lymphatic Emboli in Inflammatory and Noninflammatory Breast Cancer: A French-Tunisian Joint Study in 337 Patients
2005
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile
2003
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers
2000
Lymphœdème du membre supérieur révélant un cancer du sein
2007
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
2012
Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study
1995
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
1996
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
2005
Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
2009
Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
2008
Conservative management of breast cancer
1986
Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.
2009
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer
2015
Glucocorticoid receptor distribution in rat testis during postnatal development and effects of dexamethasone on immature peritubular cells in vitro.
2000
Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas
1987
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
2006
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
2015
Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial
2005